Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 The improved access to ... in the developing world, has led to the decline ... of deaths due to AIDS globally. However, despite the ... of new patients becoming affected by the virus is ... undertaken by all related organisations and stakeholders, by 2015, ...
Breaking Medicine News(10 mins):Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3
... stop trial-and-error warfarin dosing , FRIDAY, Sept. 7 (HealthDay ... anti-clotting drug warfarin should make it easier to prescribe ... , Up to this point, doctors have had to ... left patients at risk of hemorrhaging from low doses ...
... Ability to Improve Patient Care, LYNWOOD, Calif., ... Center have reached a tentative agreement on a ... increase their ability to,advocate for improved patient care, ... qualified and skilled staff. The agreement, which ...
... Concentra ("Concentra" or the,"Company"), a leader in on-site ... at the construction site of the former World,Trade ... workers a,convenient way to treat work related injuries. ... site treat construction,personnel, building partners, and other individuals ...
... AdvaMed General Counsel,Christopher White issued the following statement ... Patent Reform Act of 2007:, "The closely ... the significant bipartisan opposition to the patent reform,plan ... by,making patents easier to challenge and cheaper to ...
... Zimmer,Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), ... (TSX-Venture: OSH), a leader in computer,navigation for orthopaedic ... Acquisition Co., has mailed today its offer and,circular ... takeover bid for all of ORTHOsoft,s outstanding common ...
... 650,000 hospital visits, U.S. study finds , FRIDAY, Sept. 7 (HealthDay ... both the little one and his or her family from getting ... U.S. children between six months and five years old got their ... visits due to flu could be prevented. , "We found that ...
Cached Medicine News:Health News:Researchers Find Better Way to Deliver Blood Thinner 2Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Concentra Opens On-Site Medical Unit at World Trade Center Site 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 3Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 4Health News:Child's Flu Shot Helps Whole Family 2
Transcranial Doppler dedicated to intensive care unit and operating theatre....
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
The portable, cost-effective system designed for fast studies and bedside reporting. The size, features and cost make this a perfect unit for a new practice, or as a second or third unit for larger h...
Medicine Products: